Calando Finds Partner for Non-RNAi Technology, Has No Plans to Restart In-House RNAi Programs | GenomeWeb

By Doug Macron

Arrowhead Research said this week that its Calando Pharmaceuticals subsidiary has signed a deal granting the exclusive, worldwide rights to its cyclodextrin co-polymer drug-delivery technology, as well as a phase I, non-RNAi cancer drug, to Cerulean Pharma.

In doing so, Arrowhead has taken a significant step forward in its efforts to find partners for Calando's drug-development programs and delivery technologies as it struggles under a severe cash crunch.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.